Last reviewed · How we verify
Imidafenacin tablet
Imidafenacin tablet is a Small molecule drug developed by Astellas Pharma Inc. It is currently FDA-approved.
Imidafenacin is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat Overactive Bladder, specifically Overactive Bladder (OAB), as indicated by clinical trials.
At a glance
| Generic name | Imidafenacin tablet |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. (PHASE4)
- Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. (PHASE3)
- Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imidafenacin tablet CI brief — competitive landscape report
- Imidafenacin tablet updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about Imidafenacin tablet
What is Imidafenacin tablet?
Who makes Imidafenacin tablet?
What development phase is Imidafenacin tablet in?
Related
- Manufacturer: Astellas Pharma Inc — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing